article thumbnail

STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system

STAT

billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…

article thumbnail

Opinion: Want to keep schools safe? Hire more nurses

STAT

According to the New York Times, “Since 2017, tens of millions have been spent by the federal government on mass shooter training, and states have spent even more.” 

355
355
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: To mitigate drug shortages, a new study suggests looking at Canada

STAT

Between 2017 and 2021, regulators in the U.S. Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem.

342
342
article thumbnail

STAT+: DOJ probes device maker whose test resulted in lucrative diagnoses for UnitedHealth and other insurers

STAT

The company indicated that the investigation began in 2017 and picked up in intensity in late 2024 and early 2025.    The SEC filing states that on Feb.   Continue to STAT+ to read the full story…

351
351
article thumbnail

STAT+: Device maker that helped UnitedHealth collect billions offers to settle fraud claims with DOJ

STAT

The DOJ began looking into the company in 2017, according to Semler, but re-upped its investigation in late 2024 and early 2025. The deal would cap an investigation Semler first disclosed in February into whether federal health programs paid out improper claims based on the use of QuantaFlo, which would violate the False Claims Act.

278
278
article thumbnail

STAT+: Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more

STAT

billion in revenue by dispensing medicines to treat cancer, HIV, heart disease, and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022.  Specifically, the companies were able to generate more than $7.3   A federal watchdog weighed in on the U.S.

261
261
article thumbnail

Addressing Generic Drug Market Challenges: Strategies for Stability and Affordability

Drug Patent Watch

Generics 2030: Three strategies to curb the downward spiral. Retrieved from [link] The Commonwealth Fund. Strategies That Delay Market Entry of Generic Drugs. Retrieved from [link] Bollyky, T. J., & Kesselheim, A. Ten challenges in the prescription drug marketand ten solutions. Retrieved from [link] Gottlieb, S.